Format

Send to

Choose Destination
J Biol Chem. 2020 Mar 13;295(11):3401-3402. doi: 10.1074/jbc.H120.012867.

A potential new target for autoinflammatory bone disease.

Author information

1
Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research and Department of Molecular and Translational Science, Monash University, Clayton, Victoria 3168, Australia elizabeth.hartland@hudson.org.au.

Abstract

Chronic recurrent multifocal osteomyelitis (CRMO) is an autoinflammatory bone disease mediated by the inflammatory cytokine, IL-1β. Although IL-1β is known as the key driver of bone lesions in CRMO, the signaling events leading to pathogenic levels of the cytokine are not fully understood. Using a genetic mouse model of CRMO, Dasari et al. find a role for the nonreceptor spleen tyrosine kinase (SYK) in upstream signaling leading to IL-1β up-regulation. Their findings suggest that SYK may constitute a new therapeutic target for CRMO.

Conflict of interest statement

The author declares that she has no conflicts of interest with the contents of this article.

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center